Keybank National Association OH Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Keybank National Association OH trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 4.0% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,544,764 shares of the biopharmaceutical company's stock after selling 65,153 shares during the quarter. Keybank National Association OH's holdings in Pfizer were worth $39,144,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in PFE. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Up 1.1%

Pfizer stock traded up $0.28 during trading hours on Wednesday, hitting $25.32. 36,581,486 shares of the stock traded hands, compared to its average volume of 41,499,289. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm's 50-day moving average price is $23.56 and its two-hundred day moving average price is $24.83. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market cap of $143.95 billion, a PE ratio of 18.35, a PEG ratio of 0.88 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.79%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.